Find out which Indian University was the first to teach biotechnology and why it was important for science and education in ...

Spanish researchers discover AlCas12a, a groundbreaking enzyme for next-generation gene editing.The protein, discovered in wastewater, is smaller, ...

By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...

Quantumzyme Corp. (OTC: QTZM), a biotransformation company focused on enzyme-based solutions for pharmaceutical manufacturing, today announced that it plans to attend the 2026 BIO International ...

Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

This year, sales of Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity ...

Eli Lilly plans to expand its hearing loss therapy pipeline by collaborating with Seamless Therapeutics to apply the company’s next-generation gene-editing approach, based on programmable recombinases ...

The agreement with Seamless is the latest in a series of purchases and partnerships Lilly has established to build a pipeline ...

REGENXBIO Inc.  today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler ...

Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient ...